Open AccessCombined deletion of P ten and p53 in mammary epithelium accelerates triple‐negative breast cancer with dependency on e EF 2 K
Author(s) -
Liu Jeff C,
Voisin Veronique,
Wang Sharon,
Wang DongYu,
Jones Robert A,
Datti Alessandro,
Uehling David,
Alawar Rima,
Egan Sean E,
Bader Gary D,
Tsao Ming,
Mak Tak W,
Zacksenhaus Eldad
Publication year - 2014
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201404402
Subject(s) - pten , cancer research , kinome , pi3k/akt/mtor pathway , triple negative breast cancer , protein kinase b , biology , gene silencing , breast cancer , cancer , signal transduction , microbiology and biotechnology , gene , biochemistry , genetics
The tumor suppressors Pten and p53 are frequently lost in breast cancer, yet the consequences of their combined inactivation are poorly understood. Here, we show that mammary‐specific deletion of Pten via WAP ‐Cre, which targets alveolar progenitors, induced tumors with shortened latency compared to those induced by MMTV ‐Cre, which targets basal/luminal progenitors. Combined Pten‐p53 mutations accelerated formation of claudin‐low, triple‐negative‐like breast cancer ( TNBC ) that exhibited hyper‐activated AKT signaling and more mesenchymal features relative to Pten or p53 single‐mutant tumors. Twenty‐four genes that were significantly and differentially expressed between WAP ‐Cre:Pten/p53 and MMTV ‐Cre:Pten/p53 tumors predicted poor survival for claudin‐low patients. Kinome screens identified eukaryotic elongation factor‐2 kinase ( eEF 2K) inhibitors as more potent than PI3K/ AKT / mTOR inhibitors on both mouse and human Pten/p53‐deficient TNBC cells. Sensitivity to eEF 2K inhibition correlated with AKT pathway activity. eEF 2K monotherapy suppressed growth of Pten/p53‐deficient TNBC xenografts in vivo and cooperated with doxorubicin to efficiently kill tumor cells in vitro . Our results identify a prognostic signature for claudin‐low patients and provide a rationale for using eEF 2K inhibitors for treatment of TNBC with elevated AKT signaling.